New Technology for Assessing Ovarian Cancer Risk in Pelvic Masses

Ovarian cancer is rare, but it’s one of the top gynecologic cancer killers. Every year, thousands of women are diagnosed with pelvic masses which raises concern about the presence of ovarian cancer. Previously, physicians and patients might have felt that the only way to “be safe” when a woman presented with an mass was to remove the ovaries. Now, there is a company dedicated to changing this.

Aspira Women’s Health has developed a non invasive test,  OvaWatch^SM, intended for use in assessing the risk of ovarian cancer for women with adnexal masses, which gives confidence in a low probability of malignancy to allow more women to keep their ovaries while allowing healthcare providers to focus their attention on women with more troubling masses.

Aspira Women’s Health CEO, Nicole Sandford, talks more about this test as well as her own personal journey with an adnexal mass; and, expert in the field of gynecology, Dr. Gerard Reilly, explains the importance of early detection and how he uses this test in his practice.